Boston Scientific cut its full-year 2026 sales growth guidance from 10.5%–11.5% down to 7%–8.5% on April 22, despite beating Q1 numbers. The reductions traced to weakness in three named businesses, including Watchman, where standalone procedures began declining in mid-February, and electrophysiology, where the company acknowledged competitive share losses to three commercial rivals. If you are building a company in surgical robotics, electrophysiology, structural heart, or any device category where one player currently holds dominant share, the most important question this week raises is what happens when the category restructures around you and whether the work you have actually finished travels with you when it does.
If You Are Building a Company in This Environment
Category leadership in regulated device markets has historically operated like an annuity. The first cleared product in a clinical category sets the workflow, the training pathway, the reimbursement code, and the account relationships. Once those are in place, the leader collects the cash flow that comes with being the default option. The financial models that founders, boards, and investors build all assume that the annuity decays slowly because the structural advantages compound.
Boston Scientific is the company that built two of the most defensible category positions in modern medical devices. Watchman defined the left atrial appendage closure category. Farapulse defined the pulsed field ablation category. The Q1 2026 guidance cut is the visible signal that both annuities are decaying faster than the operating model assumed. Watchman volume started declining in February, only fourteen months after a year of nearly 30% growth. Electrophysiology, where Farapulse sits, is now growing into the structural pressure of a four-way platform race with Medtronic, Johnson & Johnson, and Abbott.
Founders Who Finish is built around a set of questions that hold up exactly when the assumptions other people are making fall apart. The category-restructure dynamic visible in EP this week is one of those moments. The question is no longer whether you are positioned to win. It is whether what you have already finished is durable when the structural advantages everyone is counting on stop compounding.
The Annuity-Erosion Problem That Most Founders Have Not Modeled
The standard founder financial model in a regulated device category looks something like this. You assume that early commercial traction in a defined indication leads to expanding indications, then to reference accounts, then to a defensible market position with pricing power. The model assumes the curve is monotonic, that each milestone makes the next one easier, and that competitive entry slows once you are entrenched.
That model is not wrong. It is incomplete. It does not account for the specific moment when the second or third commercial competitor clears regulatory and starts publishing comparable outcomes data in the same patient populations. At that moment, the annuity stops being an annuity. The pricing power that came from being the only credible option starts converting to volume pressure. The training infrastructure that locked in customer relationships becomes a sunk cost that no longer differentiates. The clinical evidence base that justified premium pricing becomes the floor that competitors clear, not the ceiling that defines the category.
The Boston Scientific guide-down is what this looks like at scale, in a publicly visible business with the resources to weather it. For a startup at the same inflection point, the same dynamic plays out faster, with less margin, and against a competitive set that does not have to fund a global commercial organization to stay in the fight. The implication is not that category leadership is worthless. It is that the work a leader has actually finished, separate from the position the leader currently occupies, is what determines whether the company survives the restructure.
What Finishing Looks Like When the Category Is Being Restructured Around You
The companies that hold their position through category restructures share a pattern. They finished specific things while the annuity was paying. They built reimbursement infrastructure that travels across product generations. They generated outcomes data attached to clinical problems, not to platform versions. They built account relationships anchored to clinical champions whose professional identities outlast any specific product cycle.
Johnson & Johnson’s PERSIGMA trial, which launched at HRS 2026 this week as a head-to-head comparison of Varipulse Pro against Farapulse, is a textbook example of what a competitor does when an incumbent has not finished the comparative-evidence work. The trial exists because the incumbent’s evidence base is anchored to the platform rather than to a head-to-head proof point. That gap is what the challenger is mobilizing against. A founder reading this signal as it applies to their own business should ask the harder version of the same question: what evidence base have I actually finished, and would it survive a head-to-head trial run by a credible competitor?
The Five Questions When Category Pressure Arrives
The five-question framework in Founders Who Finish was written for the moment when the assumptions a regulated business is built on stop holding. Boston Scientific’s 2026 guidance cut is one of the cleanest concrete examples of that moment in recent device-market history. The questions look different when the category is restructuring around you.
Question 1
What are you actually finishing?
When the category structure is stable, the definition of done can drift toward platform completeness. When the category is restructuring, the only definition of done that holds is clinical-problem completeness in a specific patient population with specific evidence. Founders who finish keep the definition anchored where it survives the restructure.
Question 2
Who decides you are done?
The clinical champion who validates your finish should be the physician whose professional identity is attached to the outcome, not to the platform. Champions whose identity is tied to a specific tool become liabilities when the tool gets displaced. Champions whose identity is tied to the clinical problem stay aligned with you across product generations.
Question 3
What does your evidence actually prove?
Evidence built around platform-specific workflow proves your product works with that platform. Evidence built around clinical outcomes proves the problem is real and your solution addresses it. The distinction is the difference between a company that survives a head-to-head trial against a credible competitor and a company that does not.
Question 4
What does your path to reimbursement look like?
Reimbursement attached to a procedure code survives platform transitions. Reimbursement attached to a specific device or integration pathway may not. In a category being restructured, the founders who finished the reimbursement work early are the ones with pricing power that travels. The ones who deferred it discover the problem after the structural advantage has already eroded.
Question 5
What does the finish line look like to an acquirer?
Strategic acquirers in restructured categories pay for finished commercial assets, not for category position. The premium goes to the company whose evidence, reimbursement, and account relationships travel independently of the platform that originally generated them. If your strategic exit thesis depends on the category looking the way it looks today, the thesis is fragile in a way that the Boston Scientific guidance cut just made visible.
Founders Who Finish
The guide for founders building in regulated markets
The five-question framework for building medical device, surgical robotics, and electrophysiology companies that finish what they start, in the regulatory and clinical environment as it actually exists.
Get the Book